Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554736 | 0.82 | CD274 (0.48) | PNMTCD274ADRA2AADRA2BADRA2C | |
| SCHEMBL30833272 | 0.82 | CD274 (0.48) | PNMTCD274ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL18554685 | 0.81 | CD274 (0.47) | PNMTCD274ADRA2AADRA2BADRA2C | |
| SCHEMBL18554684 | 0.77 | CD274 (0.49) | PNMTDRD2DRD1CD274ASIC3 | |
| SCHEMBL14116965 | 0.74 | PNMT (0.47) | PNMTDRD2CD274ADRA2AADRA2B | |
| SCHEMBL20909790 | 0.74 | PNMT (0.47) | PNMTDRD2CD274ADRA2AADRA2B | |
| SCHEMBL4575618 | 0.72 | PNMT (0.50) | PNMTDRD2ADRA2AADRA2BADRA2C | |
| SCHEMBL24842428 | 0.71 | CD274 (0.49) | PNMTCD274ADRA2AADRA2BADRA2C | |
| SCHEMBL21475687 | 0.71 | ADCY6 (0.57) | PNMTADRA2AADRA2BADRA2CASIC3 | |
| SCHEMBL26318706 | 0.71 | ADCY6 (0.57) | PNMTADRA2AADRA2BADRA2CASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | claimed |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2020-12-15 | — | — | US | claimed |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-20210309613-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2021-10-07 | — | — | US | disclosed |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200207718-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO, LLC | 2020-07-02 | — | — | US | disclosed |
| EP-3337564-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | Portola Pharmaceuticals, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017034990-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309613-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | LDLR, PCSK9, CETP | PNMT 4172/4885DRD2 3803/4885DRD1 3563/4885 |
| US-10865185-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | PNMT 4243/4885DRD2 3747/4885DRD1 3441/4885 |
| US-20200207718-A1 | COMPOSITION AND METHODS OF USE OF TETRAHYDROISOQUINOLINE SMALL MOLECULES TO BIND AND MODULATE PCSK9 PROTEIN ACTIVITY | LDLR, PCSK9, CETP | PNMT 4243/4885DRD2 3747/4885DRD1 3441/4885 |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | PNMT 4172/4885DRD2 3803/4885DRD1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.